David L. MacDonald

Ngen, Inc. advanced diagnostics provides physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. The company is headquartered in San Diego, CA

Nanomix, Inc. provides nano technology solutions. It is a nanotechnology company focused on development of next generation Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings. The firm's nanoscale electronic sensors have enabled the development of the next generation of Point of Care testing systems that can be used in any setting. The company's mobile diagnostic platform performs multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample. Nanomix was founded by Alexander Zettl and Marvin L. Cohen in September 2000 and is headquartered in Emeryville, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Veramarx, Inc. develops a molecular diagnostic test for lyme disease. It provides VMX-LD, a molecular diagnostic that measures multiple biomarkers known to occur soon after Lyme disease infection. The company was founded by David L. MacDonald in January 2012 and is headquartered in Boulder, CO.

First Light Diagnostics, Inc. develops automated medical diagnostic products for the detection of microbes that cause healthcare and hospital infections. The firm offers MultiPath technology detects and counts fluorescent targets without using magnification. Its MultiPath technology is used for screening, blood infections, surgical infections, skin infections and GI infections. The company was founded by Donald Straus and is headquartered in Bedford, MA.